Clinical trials: Cellular Rejection
Kidney Transplantation, Kidney Disease
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
Alemtuzumab is a man-made antibody used to treat certain blood disorders. This study will evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system suppressing medications with or without…
- Conditions
- Kidney Transplantation, Kidney Disease, Kidney Failure
- Trial name
- NCT00183248
- Testing
- Alemtuzumab, Mycophenolate mofetil, Sirolimus
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
Hematopoietic Stem Cell Transplantation, Graft Failure
Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft…
- Trial name
- NCT07244419
- Testing
- Emapalumab 3 mg/kg, Emapalumab 10 mg/kg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Heart Transplantation
Donor Derived Cell Free DNA (Dd-cfDNA) as a Biomarker for Allograft Rejection in Heart Transplant Recipients
Following heart transplantation (HTx), lifelong immunosuppressive treatment is required to prevent the immune system from attacking, damaging, and rejecting the donor hear (allograft).
- Trial name
- TRANSCEND (NCT07886489)
- Testing
- Donor-derived cell free DNA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Interventional
Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Antibody Mediated Kidney Graft Rejection (ABMR)
Transplant rejection is one of the biggest limitations in renal transplant procedures, where the kidney can undergo an acute, late acute, or chronic transplant rejection.
- Trial name
- NCT03585855
- Testing
- MSC transplantation
- Where
- Slovenia
- Volunteers
- 4 people
- Sponsor
- University Medical Centre Ljubljana
Heart Transplant Rejection
Heartsbreath Test for Heart Transplant Rejection
The purpose of this study is to demonstrate and validate a breath test for detection of biomarkers of heart transplant rejection (Grade 2R heart transplant).
- Trial name
- Heartsbreath (NCT01397812)
- Testing
- BreathScanner 1.0, BreathLink
- Where
- 5 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Menssana Research, Inc.
Heart Transplant Rejection
A New Biomarker for the Non-invasive Diagnosis of Rejection After Heart Transplantation
This study is a prospective, observational multi-center cohort study. The study will consist of patients undergoing heart transplantation.
- Trial name
- BIODRAFT (NCT03477383)
- Testing
- donor-derived cell-free DNA (dd-cfDNA)
- Where
- 4 sites in Sweden
- Volunteers
- 134 people
- Sponsor
- Vastra Gotaland Region
Kidney Transplant Infection, Kidney Transplant Rejection
Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients
All kidney transplant recipients require immunosuppression, the net level of which is difficult to assess. Current practice in assessing immune reactivity is to monitor levels of some immunosuppressive drugs.
- Trial name
- NCT03488771
- Where
- Croatia
- Volunteers
- 150 people
- Sponsor
- Clinical Hospital Merkur
Kidney Transplant Rejection
ddcfDNA in Kidney Transplant Recipients
The objective of this study is to predict subclinical Antibody-Mediated Rejection (ABMR) occurrences in de novo DSA-positive recipients maintaining stable renal function after transplantation.
- Trial name
- NCT06013358
- Testing
- AlloSeq cfDNA
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Kidney Transplant Rejection
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants
The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living…
- Trial name
- NCT03363945
- Testing
- MDR-101
- Where
- 19 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Medeor Therapeutics, Inc.
Graft Rejection
Randomized Trial for Mixed Acute Rejection
This study is being conducted to determine how safe and effective using an immune cell (b cell) depleting therapy and/or Thymoglobulin is in patients with a kidney transplant who are experiencing certain types of rejection.
- Trial name
- NCT00771875
- Testing
- Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati
Liver Disease
Randomized Controlled Trial of ImmuKnow in Liver Transplantation
ImmuKnow detects cell-mediated immunity in solid-organ transplant recipients undergoing immunosuppressive therapy. Increasing ImmuKnow values indicate a decrease of immunosuppression and decreasing ImmuKnow values suggest an…
- Trial name
- NCT01764581
- Testing
- Tacrolimus regulation according to ImmuKnow values
- Volunteers
- 206 people
- Sponsor
- University of Bologna
Kidney Transplant Rejection
Trifecta-Kidney cfDNA-MMDx Study
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.
- Trial name
- NCT04239703
- Testing
- MMDx, Prospera, HLA antibody
- Where
- 31 sites in United States, Australia and 8 more
- Volunteers
- 300 people
- Sponsor
- University of Alberta
Renal Transplant Rejection
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
This study is being done to investigate the impact of changing immunosuppressive medications from tacrolimus (Prograf®) to sirolimus (Rapamune®) between 6 and 24 months post transplant.
- Trial name
- NCT00866879
- Testing
- Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Northwestern University
Thoracic Organ Transplantation
Genome Transplant Dynamics
Study Description: Heart and lung transplants can save lives, but long-term success is often limited by organ rejection that is hard to detect early.
- Trial name
- NCT02423070
- Where
- 7 sites in United States
- Volunteers
- 991 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Rejection Chronic Renal, Kidney Transplant Rejection
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection
Our group recently reported that tocilizumab, a humanized monoclonal antibody against the IL-6 receptor, may be effective when administered monthly to patients with chronic antibody-mediated rejection (ABMR).
- Trial name
- NCT03859388
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cedars-Sinai Medical Center
Irreversible Intestinal Failure, Allograft Rejection
Low Dose Irradiation for Small Bowel Transplant
The specific aims of this study is to improve short and long-term patient and graft survival, to reduce the incidence and severity of allograft rejection, to reduce the incidence of infection and to reduce and/or eventually…
- Trial name
- NCT00382486
- Testing
- Reduce the risk of allograft rejection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Pittsburgh
Acute Rejection of Renal Transplant, Graft Failure
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
Acute rejection after kidney transplantation should ideally be diagnosed prior to immunologic injury in a non-invasive fashion in order to improve long-term graft function.
- Trial name
- NCT05084768
- Testing
- Donor-derived cell-free DNA
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Loma Linda University
Renal Failure, Chronic
Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection
Chronic transplant rejection remains the main cause of late kidney graft loss. We showed previously that patients with pretransplant CD4 helper defects and low in-vitro IL-10 responses demonstrated an extremely low risk of acute…
- Trial name
- NCT00150891
- Testing
- Kidney transplantation, cyclosporine A, tacrolimus
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- University of Giessen
Immunosuppression, Leukemia
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor s T cells (a type of lymphocyte, or white blood cell) have been removed and then added back.
- Trial name
- NCT00353860
- Testing
- SOLEX 300i Stem Cell Selection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Liver Transplantation (LT), Immuno-suppression
Immune Biomarkers for Predicting Complications After Liver Transplantation
This multicenter prospective observational study will evaluate immune biomarkers in adults undergoing liver transplantation. The study aims to describe how immune markers change before and after transplantation and to assess…
- Conditions
- Liver Transplantation (LT), Immuno-suppression, Biomarkers / Blood, Rejection
- Trial name
- NCT07875595
- Testing
- Immune Biomarker Assessment
- Where
- 3 sites in Argentina
- Volunteers
- 60 people
- Sponsor
- Hospital Italiano de Buenos Aires